Keywords: Pfizer, China, Japan, Generics,

Pfizer to be biggest beneficiary of China pharma market, say Goldman Sachs analysts; firm also set for Japanese generics market

Article | 24 November 2009

Print This

The world’s largest drugmaker, USA-based Pfizer, is eyeing the Japanese generics market and, in an investment review of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in